BioSig Technologies (NSDQ:BSGM) today announced that it has appointed John Sieckhaus as chief operating officer.
Sieckhaus joins BioSig — a creator of a proprietary biomedical signal processing platform — with 30 years of experience in the healthcare industry. He has served in numerous leadership roles at St. Jude Medical and Abbott Labs, including SVP and GM. Most recently, Sieckhaus was VP of field clinical affairs for Abbott where he created a field clinical and monitoring team to support clinical trials across multiple business units in Abbott’s Cardiovascular portfolio.
“I am very excited to join this team and look forward to building upon the foundation of the Pure EP system and its capabilities. Focusing in the area of electrophysiology by providing better solutions in identifying and treating complex arrhythmias for our clinical customers and patients will be extremely rewarding,” Sieckhaus said in a news release.
“We are pleased to welcome John to the team as we build toward a national rollout of our leading product, Pure EP. John’s leadership experience in the electrophysiology space and his impressive track record in capturing and growing market share in the U.S. is well-aligned with our mission to bring our signal processing technology to as many hospitals as possible in the coming years,” CEO and chairperson Kenneth Londoner said in a news release. John will join Gray Fleming in helping run and grow our business while attracting additional talent to the company.”